IPP Bureau
Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
By IPP Bureau - April 06, 2024
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Aster DM Healthcare concludes separation of India and GCC businesses
By IPP Bureau - April 05, 2024
The company plans to add 1700 beds by FY27 through the organic route
Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer
By IPP Bureau - April 05, 2024
Dabur India expects mid-single digit revenue growth in Q4
By IPP Bureau - April 05, 2024
International Business is expected to register double-digit growth in constant currency terms
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
By IPP Bureau - April 05, 2024
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Abbott receives FDA approval for TriClip
By IPP Bureau - April 04, 2024
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Aurigene introduces AI/ML assisted drug discovery platform
By IPP Bureau - April 04, 2024
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Evonik unveils latest global trial results MetAMINO
By IPP Bureau - April 04, 2024
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Max CMD Abhay Soi is new president of NATHEALTH
By IPP Bureau - April 04, 2024
New leadership team announced at NATHEALTH Annual General Meeting 2024
Colgate Active Salt redefines oral hygiene with a new and improved formula
By IPP Bureau - April 03, 2024
EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
By IPP Bureau - April 03, 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names
By IPP Bureau - April 02, 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Aurobindo Pharma commissions 4 plants in Andhra Pradesh including Pen-G and 6-APA facilities
By IPP Bureau - April 02, 2024
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
